Large employers forecast ‘daunting’ 9% hike in healthcare costs next year

Employers anticipate a 9% increase in healthcare costs next year, marking the largest projected annual rise in over a decade, primarily fueled by spiking pharmacy spending, notably GLP-1s, and a growing prevalence of chronic conditions like cancer. While companies aim to reduce this to 7.6% via plan design, sustained cost pressures from prior years are compelling over half of employers to consider shifting more expenses to employees through higher premiums or deductibles. Concurrently, employers are aggressively pursuing vendor-side cost containment, including renegotiating contracts, changing pharmacy benefit managers (PBMs), and limiting GLP-1 coverage, while also bracing for potential cost shifts from government policy changes impacting commercial insurance.

Analysis

Employers are confronting a projected 9% increase in healthcare costs for the upcoming year, the most significant annual rise in over a decade, creating substantial pressure on corporate profitability. This surge follows two consecutive years where actual costs already outpaced initial forecasts, indicating a sustained and accelerating trend. The primary drivers are escalating pharmacy expenditures, which now account for 24% of total employer healthcare spend, and a higher incidence of costly chronic conditions, with cancer remaining the top cost driver for the fourth straight year. Specifically, the proliferation of high-priced GLP-1 drugs for obesity and diabetes is a major contributor, with 79% of employers seeing increased use. In response, a majority of companies are signaling a strategic shift, with half now likely to pass costs to employees through higher premiums and deductibles. Concurrently, employers are aggressively targeting vendor-side efficiencies, evidenced by over 40% actively reviewing or changing their Pharmacy Benefit Managers (PBMs) to secure better pricing and transparency. This environment is further compounded by legislative uncertainty, as potential cuts to government programs like Medicaid could shift additional costs onto the commercial insurance market, intensifying the financial burden on corporations.

Key Decisions for Investors

• Investors should anticipate margin pressure on companies with large US workforces, as the 9% surge in healthcare costs directly impacts operating expenses and may not be fully offset by cost-shifting measures.
• Re-evaluate holdings in traditional Pharmacy Benefit Managers (PBMs), as over 40% of employers are actively seeking to change vendors or renegotiate contracts, indicating significant business model risk and competitive pressure.
• While pharmaceutical companies producing GLP-1s and advanced cancer therapies face robust demand, investors must monitor the countervailing risk from employers' explicit strategies to limit coverage and control spending on these high-cost drugs.
• Factor in the potential for reduced consumer discretionary spending, as the likely transfer of rising healthcare costs to employees via higher premiums and deductibles will curtail household disposable income.